Market Overview

7 Biggest Price Target Changes For Monday

Share:
  • Wedbush lowered the price target for Stemline Therapeutics Inc (NASDAQ: STML) from $19 to $11. Stemline Therapeutics shares closed at $6.55 on Friday.
  • FBR Capital lowered Galena Biopharma Inc (NASDAQ: GALE) price target from $11 to $4. Galena Biopharma shares closed at $1.20 on Friday.
  • Needham boosted the price target on Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) from $11 to $14. Progenics Pharmaceuticals shares closed at $9.49 on Friday.
  • Evercore ISI raised the price target for CARBO Ceramics Inc. (NYSE: CRR) from $10 to $19. CARBO Ceramics shares closed at $15.32 on Friday.
  • RBC Capital increased the price target for TrueCar Inc (NASDAQ: TRUE) from $12 to $17. TrueCar shares closed at $13.23 on Friday.
  • BMO Capital raised NVIDIA Corporation (NASDAQ: NVDA) price target from $75 to $100. NVIDIA shares closed at $114.38 on Friday.
  • Wedbush cut the price target on FireEye Inc (NASDAQ: FEYE) from $14 to $11. FireEye shares closed at $10.93 on Friday.

Latest Ratings for STML

DateFirmActionFromTo
Mar 2020Cantor FitzgeraldReiteratesOverweight
Mar 2020JP MorganMaintainsOverweight
Mar 2020Aegis CapitalMaintainsBuy

View More Analyst Ratings for STML
View the Latest Analyst Ratings

 

Related Articles (GALE + STML)

View Comments and Join the Discussion!

Posted-In: Price Target ChangesPrice Target Analyst Ratings

Latest Ratings

StockFirmActionPT
PECFRAMaintains8.0
HUNCFRAUpgrades16.0
CCCFRADowngrades11.0
VOYAPiper SandlerMaintains58.0
PRUPiper SandlerMaintains64.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com